Abstract
This case report (NCT04767308) details the successful treatment of a 17-year-old patient with refractory ALK+ anaplastic large cell lymphoma (ALCL) using novel anti-CD5 CAR-T cell therapy. A critical diagnostic challenge emerged three months post-infusion: a massive expansion of therapeutic CAR-T cells in the lymph nodes clinically and histologically mimicked a cancer relapse. By employing advanced molecular profiling, including T-cell receptor (TCR) repertoire analysis and next-generation sequencing (NGS), clinicians were able to distinguish the "living drug" from malignant cells, confirming a state of complete remission.
Introduction
Treating T-cell lymphomas, such as ALK+ ALCL, remains a significant clinical challenge once they become refractory to standard chemotherapy. While Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment landscape for B-cell malignancies, its application in T-cell cancers faces unique hurdles. A primary concern is "fratricide," where CAR-T cells target and kill each other because the targeted markers (like CD5) are expressed on both the malignant cells and the therapeutic T cells.
Furthermore, this case highlights a high-stakes diagnostic dilemma: distinguishing between disease relapse and robust CAR-T cell expansion. When lymph nodes swell following infusion, standard pathology can be misleading, as activated CAR-T cells often appear "atypical" or "malignant" under a microscope, potentially leading to false-positive diagnoses and unnecessary salvage therapy.
Methods
A multi-omic diagnostic strategy was employed to monitor the patient and differentiate therapeutic cells from malignant ones:
- Anti-CD5 CAR-T Engineering: Autologous T cells were modified to target CD5. The construct included a truncated EGFR (EGFRt) as a "safety switch" for targeted elimination via cetuximab if required.
- Molecular Monitoring: Droplet digital PCR (ddPCR) quantified CAR-T transgene copy numbers in peripheral blood. Flow cytometry monitored the loss of CD5 expression and the depletion of target cells.
- Genomic Profiling: Next-generation sequencing (NGS) screened a panel of 157 lymphoma-related genes for persistent or new oncogenic mutations.
- TCR Repertoire Analysis: This served as the diagnostic "gold standard." By analyzing TCR rearrangements, the team determined if the lymph node expansion was monoclonal (indicative of cancer) or polyclonal (indicative of a therapeutic CAR-T response).
Results
The patient achieved Complete Remission (CR) and has maintained disease-free survival for over 815 days (as of August 2023).
CAR-T Kinetics and Biochemical Response
CAR-T cells peaked in the peripheral blood at day 14, representing 56.17% of total lymphocytes. This expansion correlated with significant biochemical changes, including a 13-fold increase in IL-6 and a 70-fold increase in ferritin, consistent with Grade 1 Cytokine Release Syndrome (CRS).
As shown in the figure above, TNF-α levels also exhibited a sharp peak around day 14, mirroring the CAR-T expansion kinetics and supporting the clinical observation of CRS.
The "Relapse" Mirage
Three months post-infusion, the patient presented with enlarged lymph nodes. Histopathology revealed atypical large cells and a loss of normal lymph node architecture—features typically diagnostic of lymphoma relapse. However, molecular verification proved otherwise. The T cells in the biopsy were CD5-negative and contained the CAR sequence. Crucially, TCR repertoire analysis showed no evidence of a dominant malignant clone, confirming that the "atypical" cells were actually the expanded CAR-T population.
Discussion and Limitations
This study confirms that therapeutic CAR-T cells can undergo significant morphological changes in vivo, adopting a "hyperplastic" appearance that mimics malignancy. This "relapse mirage" underscores the necessity of molecular verification (NGS and TCR analysis) over traditional histopathology in the context of T-cell directed CAR therapies.
Despite the targeting of CD5, the CAR-T cells successfully expanded and persisted without debilitating fratricide. However, the study is limited by its single-patient scope (N=1). While the results are promising, the safety and efficacy of anti-CD5 CAR-T cells require validation in larger cohorts. Additionally, the patient experienced a Grade 4 rash, highlighting that off-tumor toxicities remain a concern. Future research will focus on refining safety switches and determining if CAR-T expansion mimicking relapse is a common phenomenon in T-cell therapies.
Summary updated